Two sites can report nearly identical numbers of patients with type 2 diabetes and still have very different enrollment potential for the same trial. One has recent laboratory results and treatment records that match the protocol. The other has older diagnoses, limited medication detail and a population already engaged in competing research. On a spreadsheet, the sites may look alike. At screening, they will not.
For sponsors and CROs evaluating type 2 diabetes clinical trial sites in Miami or Puerto Rico, the task is to understand what the patient count actually represents. The useful forecast follows clinical criteria, patient contact, investigator review and available appointments through to a realistic number of participants who could enroll.
Begin with the protocol, not the diabetes label
Type 2 diabetes is not one uniform study population. A protocol may require a specific range of glycated hemoglobin (HbA1c), stable background therapy, a documented diagnosis of a minimum duration, a particular body mass index, or evidence of cardiovascular or renal risk. Those details can change the pool before anyone agrees to a screening visit.
Ask a prospective site to group criteria by what can be established from records, what must be confirmed by a clinician, and what can only be determined during protocol screening. A diagnosis code may identify someone for review, but it does not confirm current glycemic control, medication stability, willingness to participate or that a new test will meet the central laboratory threshold.
A good answer names the evidence and its limitations. It does not convert every person with a diabetes-related record into an eligible participant.
HbA1c needs a date, a method and a protocol context
HbA1c is useful because it reflects average glucose exposure over roughly three months. That does not mean every historic value is suitable for feasibility. A result from many months ago may no longer represent the person's condition, especially after treatment changes. Even a recent value may fall outside a study-specific band.
The National Institute of Diabetes and Digestive and Kidney Diseases describes how HbA1c is used for diagnosis and management, and notes that some clinical circumstances affect its interpretation. Sponsors should therefore ask whether the site can identify the result date and source, distinguish longitudinal trends from a single reading, and confirm which questions require the protocol laboratory or investigator.
Avoid applying a generic HbA1c threshold to all type 2 diabetes studies. The correct inclusion range and confirmation process come from the actual protocol and approved screening procedures.
Medication history can shrink a seemingly large pool
A patient count alone says little about whether the current regimen fits a new trial. Investigators may need to review metformin, insulin, incretin-based therapy, other glucose-lowering agents, recent dose changes, previous exposure to a study drug class, and medicines prescribed for related conditions. The relevant details depend on the protocol.
For feasibility, request a breakdown of which medication fields are reliable, which require chart review, and what requires direct confirmation with the participant and treating clinician. Pharmacy lists can be incomplete, outdated or inconsistent with what the patient is actually taking. They should not be treated as an automatic eligibility decision.
Also ask what a required stability period means for recruitment. A participant who otherwise appears suitable may be unable to enter the study immediately, and no one should alter prescribed treatment simply to fit an enrollment projection.
Review kidney, cardiovascular and other conditions without double counting
Many people with type 2 diabetes also have conditions that matter to protocol eligibility. Depending on the investigational treatment and objectives, the review might include renal function, cardiovascular history, blood pressure, eye disease, weight change, hypoglycemia history or previous procedures.
That overlap can create opportunities for a properly designed cardiometabolic study, but it can also introduce exclusions or extra assessments. The same patient should not appear as several independent opportunities merely because records include diabetes, obesity and cardiovascular diagnoses. A practical site assessment uses distinct patient records and then applies the study's specific eligibility logic.
Ask investigators to distinguish clinical questions that can be resolved through existing records from those requiring current tests, specialty review or outside appointments. Confirm that the required services are actually available at the proposed location or have a documented coordination pathway.
Separate identifiable patients from people ready for screening
An electronic medical record query is a first pass, not an enrollment commitment. The path continues through deduplication, current contact information, permitted outreach, clinical prescreening, participant interest, appointment availability, informed consent and protocol assessments. Each transition has a different reason for loss.
WCR describes this distinction in its patient-access approach: connected records and clinical relationships support feasibility, while individual eligibility is assessed for the particular study. That framework matters for diabetes because a person may attend routine primary-care visits but not have recent research-grade laboratory measures or time for additional assessments.
To test a forecast, ask for a simple funnel with the date range and evidence behind each step. Label estimated stages as estimates. Where prior study experience is relevant, make sure the comparison uses similar eligibility and screening burden rather than borrowing a high enrollment rate from an unrelated protocol.
The visit schedule is part of feasibility
Screening can involve fasting visits, laboratory collections, questionnaires, device training, medication reconciliation, or specialty assessments, depending on the protocol. Participants may be employed, caring for family, or juggling treatment appointments. A site with accessible patients but too few suitable morning slots may still struggle to convert interest into completed screenings.
Ask the coordinator to walk through the most demanding visit, not just the first. How long must a participant remain at the clinic? Which collections have time windows? Who manages outside laboratory or specialty appointments? Is bilingual communication available for explaining preparation and follow-up? What happens when a visit must be rescheduled?
The FDA's final E6(R3) Good Clinical Practice guidance emphasizes quality by design, participant protection and proportionate oversight. At site selection, that supports testing the real delivery workflow before relying on a recruitment target.
Use WCR experience as a scoped example, not a prediction
WCR's public diabetes and endocrinology program describes practice-connected patient access, clinical sample processing, temperature-controlled storage, laboratory coordination and bilingual participant support. Study and location suitability are evaluated separately, rather than presumed for every protocol.
Its publicly reported obesity-with-diabetes case study illustrates why staffing matters alongside patient access. The site screened 27 people in the first month after activation, and 13 were subsequently randomized following the protocol's screening interval. This is one documented study result, not a typical type 2 diabetes enrollment rate, a network-wide conversion ratio or a promise for a future trial.
The transferable lesson is about sequence. Candidate identification, staffing, screening appointments and participant follow-up were planned together. Sponsors should look for comparable evidence of preparedness when considering a new study.
A decision framework for the next feasibility call
Before choosing a diabetes research site, a sponsor or CRO can use a short, evidence-led review. It should be completed for the actual protocol and updated when eligibility, background therapy or planned visit procedures change.
- Population definition: Is the count based on distinct, reasonably current records with a clear date range?
- Glycemic evidence: Which HbA1c results are recent, and which participants need new tests or clinician interpretation?
- Treatment fit: Can the team review medication class, dose changes, washouts and stability requirements without assuming chart accuracy?
- Clinical exclusions: Are renal, cardiovascular and other protocol-specific conditions assessed using the correct evidence?
- Patient pathway: How many records could be reviewed, people lawfully contacted, visits scheduled and screenings completed?
- Visit delivery: Are staffing, fasting appointments, equipment, central labs and outside referrals workable at the requested location?
- Forecast ownership: Who will update assumptions as screening data arrive, and how will reasons for screen failure be tracked?
Choose the site that can explain the numbers
The strongest feasibility response is not necessarily the one with the largest diabetes database. It is the one that identifies what is known today, what requires verification, what the protocol may exclude and what the site can reasonably execute within the enrollment window.
For a proposed type 2 diabetes study in South Florida or Puerto Rico, sponsors and CROs can share nonconfidential protocol requirements through WCR's existing study inquiry form. The next conversation should establish investigator fit, site-specific capacity and the assumptions needed to produce a credible recruitment plan.